Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 4, Pages 1010
Publisher
MDPI AG
Online
2020-04-21
DOI
10.3390/cancers12041010
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting
- (2019) Shuntaro Obi et al. Hepatology International
- Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma
- (2019) Lorenza Rimassa et al. CANCER TREATMENT REVIEWS
- Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma
- (2019) AYA TAKAHASHI et al. ANTICANCER RESEARCH
- REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset
- (2019) Tatsuya Yamashita et al. JOURNAL OF GASTROENTEROLOGY
- Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings
- (2019) Sasaki et al. Cancers
- Dose Intensity/Body Surface Area Ratio is a Novel Marker Useful for Predicting Response to Lenvatinib against Hepatocellular Carcinoma
- (2019) Yuji Eso et al. Cancers
- Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study
- (2018) Sheng-Long Ye et al. BMC CANCER
- Cancer Lipid Metabolism Confers Antiangiogenic Drug Resistance
- (2018) Hideki Iwamoto et al. Cell Metabolism
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Optimal management of patients with hepatocellular carcinoma treated with lenvatinib
- (2018) Masafumi Ikeda et al. Expert Opinion On Drug Safety
- PRIMARY ADRENAL INSUFFICIENCY DURING LENVATINIB OR VANDETANIB AND IMPROVEMENT OF FATIGUE AFTER CORTISONE ACETATE THERAPY
- (2018) Carla Colombo et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis
- (2018) Atsushi Hiraoka et al. Cancer Medicine
- Systemic Therapy for Hepatocellular Carcinoma: Latest Advances
- (2018) Masatoshi Kudo Cancers
- Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor
- (2017) Ziad Hussein et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma
- (2017) Carolien M Beukhof et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses
- (2017) Toshiyuki Tamai et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Off-tumor targets compromise antiangiogenic drug sensitivity by inducing kidney erythropoietin production
- (2017) Masaki Nakamura et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
- (2016) Jordi Bruix et al. GASTROENTEROLOGY
- Hypothyroidism Side Effect in Patients Treated with Sunitinib or Sorafenib: Clinical and Structural Analyses
- (2016) Mao Shu et al. PLoS One
- Hepatocellular carcinoma: From diagnosis to treatment
- (2016) Miral Sadaria Grandhi et al. SURGICAL ONCOLOGY-OXFORD
- Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism
- (2016) Yunlong Yang et al. Nature Communications
- Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
- (2015) M. Ikeda et al. CLINICAL CANCER RESEARCH
- New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions
- (2015) Makoto Chuma et al. HEPATOLOGY RESEARCH
- PlGF-induced VEGFR1-dependent vascular remodeling determines opposing antitumor effects and drug resistance to Dll4-Notch inhibitors
- (2015) H. Iwamoto et al. Science Advances
- Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis
- (2014) Omar Abdel-Rahman et al. Expert Review of Anticancer Therapy
- Modulation of age-related insulin sensitivity by VEGF-dependent vascular plasticity in adipose tissues
- (2014) J. Honek et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan
- (2014) Masatoshi Kudo et al. Liver Cancer
- Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues
- (2013) Y. Yang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version
- (2011) Masatoshi Kudo et al. DIGESTIVE DISEASES
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More